Trial register facet
Trial records for Tirzepatide — page 2
63 records for Tirzepatide, of which 16 are published trials.
Showing 0 records on this page
Records
63 documents · page 2 of 3
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SYNERGY-NASH-BODY-COMPprogramme record | Tirzepatide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-4-REGIONAL-CNprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SUMMIT-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| SURMOUNT-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 938 | 2023 | High |
| SURMOUNT-3 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 806 | 2023 | High |
| SURMOUNT-2-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-3-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-2-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-3-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-2-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-3-QOLprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-2-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| SURMOUNT-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 2,539 | 2022 | High |
| SURPASS-5 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 475 | 2022 | High |
| SURMOUNT-1-OLEprogramme record | Tirzepatide | Phase 3 | Reported | Single-arm open-label | — | 2022 | Very low |
| SURPASS-5-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| SURMOUNT-1-ELDERLYprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| SURPASS-5-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| SURPASS-5-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| SURPASS-1 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 478 | 2021 | High |
| SURPASS-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, active-controlled | 1,879 | 2021 | High |
| SURPASS-3 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 1,444 | 2021 | High |
| SURPASS-4 | Tirzepatide | Phase 3 | Reported | Randomised, open-label, active-controlled | 2,002 | 2021 | High |
page 2 of 3